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Abstract
Background: Men have a greater risk of colorectal cancer (CRC) than women, but
population screening currently starts at the same age for both sexes.
Aim: This analysis investigates whether, in a resource-constrained setting, it would
be more effective and cost-effective for men and women to start screening for CRC
at different ages.
Methods and results: An economic modeling analysis was carried out using the
Microsimulation Model in Cancer of the Bowel to compare sex-stratification against
screening everyone from the same age, taking an English National Health Service
perspective. Screening men from age 56 and women from age 60, rather than
screening everyone from age 58 using a Fecal Immunochemical Test (FIT) threshold
of 120 μg/g is expected to produce an additional 0.0004 QALYs for a cost of £0.55
per person at model start (Incremental Cost-effectiveness Ratio = £1392), and to
reduce CRC cases and mortality by 25 and 19 per 100 000 people respectively,
while using a similar amount of screening resources. Probabilistic sensitivity analy-
sis indicates a 61% probability that sex-stratification is more cost-effective than
screening everyone at age 58. Similar benefits of sex-stratification are found at
other FIT thresholds, but become negligible if mean screening start age is reduced
to 50.
Conclusion: Where resources are constrained and it is not feasible to screen every-
one from the age of 50, starting screening earlier in men than women is likely to be
more cost-effective and gain more health benefits overall than strategies where men
and women start screening at the same age.
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1 | INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer in men and
the second in women worldwide.1 There is good evidence that
population-wide screening reduces both CRC incidence and mortality,2
and is cost-effective compared with no screening, irrespective of the
screening modality used.3 These benefits of screening, together with
the increase in incidence of CRC among younger individuals,4 have led
many countries to reduce the starting age of screening. For example,
the UK National Screening Committee has recommended to reduce the
start age of biennial screening with fecal immunochemical testing (FIT)
from 60 years (as it is currently in England) to 50 years.5 However, the
incidence of CRC and CRC-related mortality is higher in men than
women6: global incidence of CRC is higher in males (746 298 vs
614 304 annually) across all WHO regions and similar trends are noted
for CRC-related mortality with a higher global burden in males (373 639
vs 320 294 annually). Additionally, the location of cancer within the
bowel differs between the sexes7,8 and CRC occurs at an earlier age in
men.8,9 The performance of screening tests also differs between men
and women: for example, fecal immunochemical testing (FIT) has better
performance characteristics with a higher sensitivity for advanced neo-
plasia and positive predictive value, and a lower specificity and false
positive rate in men than women.10-12 Furthermore, men are less likely
to take up screening than women, thus exacerbating inequalities.13
These differences have led to proposals that CRC screening
should be stratified by sex.9,14-16 However, worldwide no current
CRC screening guidelines include sex-specific recommendations.17
Most previous cost-effectiveness analyses of screening have also not
considered men and women separately.18 The only study that consid-
ered men and women separately used sex-specific versions of the
MISCAN-Colon model. That study showed that optimal screening
strategies were similar in men and women with respect to interval,
age range, and FIT cutoff and although for strategies with few screen-
ing rounds sex-stratified screening dominated uniform screening for
both sexes, the differences were small.19 However, that study did not
consider constraints on resources that operate in practice, with opti-
mal strategies comprising of intensive screening using lower FIT
thresholds and lower starting ages than are commonly used world-
wide.20 Furthermore, differences in uptake between men and women
were not considered, but these have important implications for effi-
cacy of screening programs in practice. In order to inform the planned
reduction in starting age of screening in England and other countries,
we aimed to investigate whether, in a situation of constrained
resources, planned reductions in FIT screening start age should be
uniform across the population, or stratified by sex.
2 | MATERIALS AND METHODS
2.1 | Model background
This analysis uses an individual patient-level microsimulation model:
Microsimulation Model in Cancer of the Bowel (MiMiC-Bowel)
developed in 2019. A detailed description of modeling methods can
be found online.21 The model has a lifetime horizon and takes an
English NHS perspective. Patient baseline characteristics are taken
from the Health Survey for England (2014), in order to represent the
population of England.22 All patients are assumed to be age 30 with
normal colorectal epithelium at model start. MiMiC-Bowel contains a
natural history module with patients moving through up to nine differ-
ent health states representing normal epithelium, low- and high-risk
adenoma, CRC stages A to D, and death from CRC or other causes.
Transitions between health states were derived through calibration to
find parameter sets that enabled the model to replicate age- and sex-
specific differences in CRC incidence and prevalence of adenomas
and undiagnosed CRC in the absence of CRC screening. CRC mortality
rates were calculated by age, sex, stage at diagnosis, and year from
diagnosis, while other cause mortality was based on age and sex only.
In the model patients with CRC may be detected via screening or
clinically via symptomatic/chance presentation. Modeled screening
procedures are based on the English Bowel Cancer Screening Pro-
gramme (BCSP), with positive results leading to further investigation
by colonoscopy. Patients found to have adenomas undergo
polypectomy and British Society of Gastroenterology guidelines are
implemented in the model for surveillance following adenoma
removal.23 Complications of endoscopy include perforation, major
bleed, and mortality. The model incorporates sex- and age-specific dif-
ferences in uptake of screening and follow-up procedures, and screen-
ing sensitivity and specificity. All modeled procedures are assumed to
incur costs and resource use, with average CRC treatment costs vary-
ing by age, stage at diagnosis, and year from diagnosis. All patients
have an individual health-related quality-of-life, which is subject to
decrements based on age, CRC diagnosis, and endoscopy
complications.
2.2 | Model analyses
The current FIT screening strategy in England (biennial FIT at a thresh-
old of 120 μg/g [FIT120], age 60-74; eight screening episodes in total)
was chosen as the comparator for incremental cost-effectiveness
analysis. As there are plans for the start age for CRC screening to be
reduced, the primary analysis asked the question whether it would be
more cost-effective and beneficial to health to reduce screening start
age by 2 years to age 58 in all individuals (nine screening episodes
in total for all individuals), or whether instead screening start age
should be reduced by 4 years to age 56 in males, and kept at age
60 in females (10 screening episodes for males and 8 in females,
approximate average of 9 screening episodes in total). This com-
parison was chosen for two reasons. Firstly, it was important to
keep the total number of screening episodes, and hence screen-
ing resource uses approximately the same between intervention
and comparator to ensure that any benefits of sex-stratified
screening could be attributed to the stratification itself and not
to performing more screening overall. This is necessary because
previous work has indicated that lowering screening start age in
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all individuals is cost-effective and reduces CRC incidence and
mortality, but is currently not feasible in England due to resource
constraints.24 Secondly, Cancer Research UK incidence data indi-
cate that 10 year cumulative incidence of CRC is approximately
the same (0.85%) in males aged 56 and females aged 60.25 Conse-
quently, choosing a starting age of 56 in males and 60 in females
would mean that, on average, the estimated 10-year CRC risk
would be the same for both sexes when first invited for screen-
ing. In order to ascertain whether benefits were due specifically
to stratification by sex, a further analysis was done in which a
randomly selected 50% of the population were screened from age
56, with the other half screened from age 60.
A set of alternative scenario analyses were then carried out to
look at the benefits of sex-stratification with (a) lower FIT thresh-
olds (FIT80 and FIT20); (b) a younger mean start age (age 54 or
age 50); (c) lower FIT threshold and younger mean start age
(FIT20 at age 50); (d) a different number of years (2, 4, 6 or 8)
between the starting age for screening in men and women; and
(e) a different discount rate for costs and QALYs (1.5% and 5%,
compared to the 3.5% used in the base case analysis) (Table S1).
For all analyses, strategies with the same mean starting age and
same mean number of screening episodes were compared. For
strategies in which males and females started screening at an even
numbered age, all individuals were invited for their last screen at
age 74. For strategies in which males and females started screen-
ing at an odd numbered age, males were assumed to finish screen-
ing at age 73, while females were assumed to finish screening at
age 75, which ensured that the mean number of screening epi-
sodes was the same as the fixed age comparator (eg, screening
men from age 57 to 73 and women from 59 to 75, which is
9 screening episodes each).
We modeled the cost-effectiveness, health benefits, and
resource use for each strategy using probabilistic sensitivity anal-
ysis (PSA), to enable parameter uncertainty to be incorporated.
Discount rate was set at 3.5% for costs and QALYs unless other-
wise stated. Cost-effectiveness was measured using the incre-
mental cost-effectiveness ratio (ICER) and net monetary benefit
(NMB), assuming a willingness to pay threshold of £20 000 per
QALY. Outcomes were collected per person in the whole popula-
tion and by sex.
3 | RESULTS
Reducing FIT screening start age from 60 to 58 is cost-effective
(Figure 1 & Table S2), producing 0.0012 QALYs for a cost of £3.28 per
person in the population at model start (ICER = £2634). Over a life-
time horizon, the strategy is expected to result in 84 fewer CRC cases,
93 fewer late stage CRC cases, and 66 fewer CRC mortalities per
100 000 population (a 1.3% reduction in CRC incidence and a 2.1%
reduction in CRC mortality overall). It is anticipated that this will
require an additional 451 screening colonoscopies per 100 000 popu-
lation compared to current care (an increase of 6.6%). On average,
men gain slightly more health benefits from this strategy than women,
but also incur greater costs and use slightly more resources, which are
explained by their higher underlying risk and hence ability to benefit
from screening.
Screening men from age 56 but keeping the screening start age at
60 for women is more cost-effective than screening everyone from
age 58 (Figure 1 & Table S2), producing an additional 0.0004 QALYs
for a further cost of only £0.55 per person in the population at model
start (ICER = £1392). Probabilistic sensitivity analysis indicates that
there is a 61% probability that this sex-stratified approach is more
cost-effective than screening everyone at age 58, assuming a willing-
ness to pay threshold of £20 000 or £30 000 per QALY (Figure 2).
Greater health benefits are also produced, with an additional reduc-
tion of 25 CRC cases, 28 late stage CRC cases and 19 CRC mortalities
per 100 000 people in the population, compared to screening every-
one from 58. As expected, all the additional health benefits are gained
by men. This is in the context of similar resource use; slightly fewer
FIT tests are required for sex-stratified screening (due to there being
slightly fewer men than women at screening start age) but somewhat
more screening colonoscopies are required (a further 185 per
100 000 population), reflecting the higher CRC risk level and hence
greater number of positive screening tests in men. Random screening
of 50% of the population from age 56 and 50% from age 60 only pro-
duces a small fraction of the benefits of sex-stratified screening, com-
pared with screening everyone from 58 (Figure 1 & Table S2). These
small benefits of random stratification compared with screening all at
age 58 are likely to be explained by the benefits of half the population
starting screening 2 years earlier outweighing the disadvantages of
the other half starting screening 2 years later (higher uptake and posi-
tivity of screening in the larger younger group).
Scenario analysis indicates that screening at different FIT thresh-
olds has little impact on the benefits of sex stratification (Figure 3,
panel A and Table S3). However, benefits to the population as a whole
are considerably smaller if younger mean start age strategies are com-
pared, with there being little difference in overall net monetary bene-
fit or reductions in CRC mortality between screening all individuals
from age 50, vs screening men in their late 40s and women in their
early 50s (Figure 3, panel B and Table S4). While sex-stratified screen-
ing strategies with an average starting age of 50 years do benefit men
more than women, the differences between the sexes are smaller
compared to starting screening at age 58 on average, and almost can-
cel each other out. Similar results are found at a lower FIT threshold
(Table S5). The number of years between male and female screening
starting age also impacts on the results (Figure 3, panel C and
Table S6). Compared with screening everyone at age 58, the optimal
sex-stratified strategy is to screen men at age 56 and women at age
60, which corresponds with differences between the sexes seen in
CRC incidence data.25 In general, strategies that start at odd-
numbered ages and finish at age 73 for men and age 75 for women
are less cost-effective and less beneficial to health than those where
screening starts at even-numbered ages and both men and women
finish screening at age 74. Increasing or reducing the discount rate for
costs and QALYs has the expected impact in reducing or increasing
THOMAS ET AL. 3 of 7
F IGURE 2 Cost-effectiveness
acceptability curves indicating (a) the
probability that sex-stratified
screening (men starting at age 56 and
women starting at age 60) is the most
cost-effective option compared with
no stratification (screening everyone
from age 58); (b) the most cost-
effective strategy when comparing
the comparator (screening everyone
at age 60), with no stratification
(screening everyone at age 58),
randomly stratified (half starting at
age 56 and half starting at age 60),
and sex-stratified (men starting at age
56 and women starting at age 60); at
a range of different willingness to pay
thresholds measured in £ per quality-
adjusted life-year (QALY)
F IGURE 1 Incremental lifetime cost-effectiveness outcomes, health benefits, and resource use for men, women, and averaged over the
population per person at model start for (A) screening all individuals from age 58 (no stratification); (B) screening men from age 56 and women from
age 60 (sex-stratified); (C) randomly screening half the population from age 56 and half from age 60 (randomly stratified). All incremental results are
compared with screening all individuals from age 60 and are based on screening for colorectal cancer (CRC) with the fecal immunochemical test (FIT)
at 120 μg/g. Net monetary benefit is calculated by assuming a willingness to pay threshold of £20 000 per quality-adjusted life year (QALY)
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(respectively) the magnitude of absolute and incremental health bene-
fits and net monetary benefit produced (Table S7), but does not
change the probability of cost-effectiveness, or the conclusions of the
analysis.
4 | DISCUSSION
Men have a higher risk of CRC than women and currently suffer a
greater burden of morbidity and mortality relating to CRC; however,
no current screening programs differ in their criteria for men and
women. This analysis shows that if resources are not available to
screen all individuals from a young age, starting screening at a
younger age for men than women would not only go towards reduc-
ing the disproportional disease burden in men, but is also likely to be
more cost-effective and gain more health benefits overall than strate-
gies with equivalent number of screening episodes and similar
resource use, in which men and women start screening at the same
age. It, therefore, represents a way of improving screening efficiency
and inequalities between the sexes in CRC outcomes without incur-
ring substantial additional resource use or costs.
If resources become available to enable all individuals to be
screened at a younger age, the improvements in efficiency of sex
stratification diminish, becoming marginal if everyone is screened
from age 50, no matter which FIT threshold is chosen. This result sup-
ports the findings of the MISCAN modeling,19 which did not find a
F IGURE 3 Scenario analysis showing the incremental benefits produced through reducing screening start age without stratification, or with
sex stratification at: (A) different fecal immunochemical test (FIT) screening thresholds (in all cases, sex stratification means men screened from
age 56 and women screened from age 60); (B) different mean start ages (in all cases, at FIT120 and sex stratification means men screened 4 years
earlier than women); (C) different age gaps for screening start by men and women (in all cases, at FIT120 and note that where screening starts at
an odd numbered age, it ends at 73 in men and 75 in women to keep mean number of screening episodes constant). All incremental results are
compared with screening all individuals from age 60. Net monetary benefit is calculated by assuming a willingness to pay threshold of £20 000
per quality-adjusted life year (QALY)
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significant benefit for sex-stratified screening strategies when consid-
ering very high resource use scenarios including low FIT thresholds,
young starting ages, and shorter screening intervals. Our findings
show that there are likely to be significant benefits to sex stratifica-
tion in a resource-constrained situation.
Basing the starting age of screening on sex would be logistically
easy to implement, and incur no additional costs outside those
required for following up additional positive test results. It may,
therefore, be attractive to policy makers both in countries with exis-
ting screening programs, such as England, where endoscopy capacity
is limited, and in countries yet to introduce population-wide screen-
ing or facing additional resource constraints following the covid-19
pandemic. In many countries, there is also already a precedent for
considering men and women differently within national screening
programs. In England, for example, breast and cervical cancer screen-
ing is carried out only in women. Research is needed to assess the
public acceptability of varying the starting age for screening based
on sex.
This analysis used a model with a population representative of
England, and that takes into account sex differences at almost all
stages of the CRC natural history and screening pathways, and there-
fore is likely to provide a fairly accurate estimate of how the benefits
of CRC screening differ by sex. However, model uncertainty is high
due to wide confidence intervals around many of the model parame-
ters. These include FIT screening characteristics, which are derived
from the relatively small numbers in the UK FIT pilot (FIT was only
rolled out from mid-2019 in England), the utility decrements for peo-
ple diagnosed with CRC, and uncertainties around the data used to
calibrate the model natural history, much of which is based on the old
Dukes staging system rather than the now more commonly used
TNM system. Improvements in data collection from CRC patients
should enable modeled uncertainty to be reduced in future analyses.
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